Prokanatide (Plecanatide) is a new drug affecting guanylate cyclase, which can stimulate intestinal secretion of intestinal fluid and accelerate defecation. An oral polypeptide composed of 16 amino acids designed to mimic the human gastrointestinal peptide, uranyin. Pucanatide, originally developed by Callisto Pharmaceuticals and transferred to Synergy Pharmaceuticals, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CIC in adults on January 19, 2017. Pucanatide is an analogues of uroguanylin, a cyclic polypeptide Chemicalbook containing 16 amino acids. It acts as a guanylate cyclase receptor agonist for sodium excretion, regulating acid and base ions in the gastrointestinal tract, inducing fluid transport into the gastrointestinal tract, and increasing gastrointestinal peristalsis. Mechanism of action Pucanatide and its active metabolites bind to GC-C enzymes and act locally on the lumen surface of intestinal epithelial cells. The activation of GC-C enzyme increases the concentration of intracellular and extracellular cyclic guanosine phosphate (cGMP), while the increase of intracellular cGMP concentration mainly stimulates the secretion of chloride and bicarbonate into the intestinal lumen through the ion channel activation of cystic fibrosis transmembrane regulatory factor (CFTR), which increases and speeds up the passage of intestinal fluid.Email : salesexecutive1@yeah.net whatsapp: +8618931626169 wickr: lilywang